Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

cst pharma ltd - trifluoperazine hydrochloride - oral solution - 200microgram/1ml

Zimbabwe - anglais - Medicines Control Authority

remedica ltd - trifluoperazine hydrochloride - tablet, coated; oral - 5mg

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - trifluoperazine hydrochloride - oral solution - 1mg/1ml

Tanzanie - anglais - Tanzania Medicinces & Medical Devices Authority

remedica ltd, cyprus - trifluoperazine - tablet, film-coated - 5

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - trifluoperazine hydrochloride - oral suspension - 200microgram/1ml

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - trifluoperazine hydrochloride - oral tablet - 1mg

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - trifluoperazine hydrochloride - oral solution - 1mg/1ml

Malte - anglais - Medicines Authority

mercury pharmaceuticals limited capital house, 85 king william street, london ec4n 7bl, united kingdom - trifluoperazine hydrochloride - syrup - trifluoperazine hydrochloride 1 mg/5ml - psycholeptics

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - trifluoperazine hydrochloride 1.18mg equivalent to 1 mg trifluoperazine;   - film coated tablet - 1 mg - active: trifluoperazine hydrochloride 1.18mg equivalent to 1 mg trifluoperazine   excipient: calcium sulfate dihydrate gelatin maize starch opadry blue oy-4492 purified talc purified water as solvent stearic acid sucrose - chronic therapy in high doses for management of manifestations of psychotic disorders, such as acute and chronic catatonic hebephrenic and paranoid schizophrenia, psychosis due to organic brain damage, toxic psychosis, manic depressive psychosis, senile psychosis and mental deficiency. short-term therapy treatment of acute alcoholism for the relief of delusons, hallucinations and confused state, and for the control of accompanying tremulousness and aggressive behaviour. in low doses to control excessive anxiety, tension and agitation as seen in neuroses or associated with somatic conditions. stelazine is not recommended as first line therapy in patients with non-psychotic anxiety disorders, nor should therapy be carried out for more than 12 weeks. for nausea and vomiting of various causes.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - trifluoperazine hydrochloride 2.36mg equivalent to 2 mg trifluoperazine;   - film coated tablet - 2 mg - active: trifluoperazine hydrochloride 2.36mg equivalent to 2 mg trifluoperazine   excipient: calcium sulfate dihydrate gelatin maize starch opadry blue oy-4492 purified talc purified water as solvent stearic acid sucrose - chronic therapy in high doses for management of manifestations of psychotic disorders, such as acute and chronic catatonic hebephrenic and paranoid schizophrenia, psychosis due to organic brain damage, toxic psychosis, manic depressive psychosis, senile psychosis and mental deficiency. short-term therapy treatment of acute alcoholism for the relief of delusons, hallucinations and confused state, and for the control of accompanying tremulousness and aggressive behaviour. in low doses to control excessive anxiety, tension and agitation as seen in neuroses or associated with somatic conditions. stelazine is not recommended as first line therapy in patients with non-psychotic anxiety disorders, nor should therapy be carried out for more than 12 weeks. for nausea and vomiting of various causes.